Tempest (NASDAQ:TPST) announced a significant shift in its corporate trajectory on March 30, 2026, reporting year-end 2025 financial results alongside a strategic move toward partner-funded development.
The company highlighted the completion of an all-stock acquisition of dual-targeting CAR-T assets from Factor Bioscience, a move designed to bolster its oncology pipeline without immediate cash outlays.
Clinical progress remained a focal point for the firm, led by positive interim data from the REDEEM-1 trial.
The company reported a 100% complete response (CR) rate in six evaluable patients treated with TPST-2003.
Additionally, Tempest noted that its lead candidate, amezalpat, has secured key regulatory designations, clearing a path for continued clinical maturation.
The corporate update comes as Tempest navigates a narrowing capital base.
Cash and cash equivalents fell to $7.7 million at the end of 2025, down from $30.3 million the previous year.
The company reported a net loss of $26.3 million for the full year, with research and development expenses totaling $12.6 million.
To address its capital requirements, Tempest successfully completed multiple equity financings throughout the year.
However, management signaled a tactical shift in its fiscal approach, stating that future development will increasingly rely on partner-funded strategies to advance its clinical programs.